We found that anlotinib stopped the proliferation, migration, and invasion effects in the ICC cells that were caused by recombinant human VEGF (rhVEGF); siVEGFR2 decreased the effects of anlotinib in the ICC cells (Fig. 6a–c). This evidence concerns the gene VEGFA and intrahepatic cholangiocarcinoma.